INAB Profile
IN8bio, Inc. is a clinical-stage biotechnology company dedicated to advancing gamma-delta T cell therapies for cancer treatment. The company’s primary focus is on developing and commercializing innovative therapies that harness the unique properties of gamma-delta T cells, which are believed to offer potent anti-tumor activity. IN8bio's lead product candidate, INB-200, is an autologous gamma-delta T cell therapy that has been genetically modified to enhance its efficacy. This product is currently undergoing Phase I clinical trials to evaluate its safety and efficacy in treating glioblastoma and other solid tumors.
The company is also advancing INB-100, an allogeneic gamma-delta T cell therapy that is being tested in Phase I clinical trials for patients with acute leukemia who are undergoing hematopoietic stem cell transplantation. This product aims to provide a broader treatment option that does not rely on the patient’s own cells, potentially offering more accessible therapy for a wider range of patients. Additionally, IN8bio is developing two preclinical product candidates, INB-400 and INB-300, which are targeted at treating various solid tumor cancers. These therapies are still in the early stages of development but hold promise for expanding the company’s portfolio.
IN8bio’s innovative approach to cancer treatment is underpinned by its robust research and development pipeline, which leverages the unique capabilities of gamma-delta T cells. These cells have shown potential in targeting tumors with minimal off-target effects, offering a novel avenue for treating cancers that are otherwise difficult to address with traditional therapies. The company’s strategic focus on advancing these therapies through clinical trials reflects its commitment to addressing unmet medical needs in oncology.
Originally known as Incysus Therapeutics, Inc., IN8bio underwent a rebranding to its current name in August 2020 to better reflect its new strategic direction. Established in 2016 and headquartered in New York, IN8bio continues to build on its foundational research and development efforts as it aims to bring transformative cancer therapies to market. The company’s evolving pipeline and clinical progress underscore its role in the burgeoning field of cellular immunotherapy.
|
